BTIG analyst Thomas Schrader reiterated a Buy rating and $11.00 price target on Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Form 10-Q Acumen Pharmaceuticals, For: Jun 30August 13, 2024 4:43 PM Form 8-K Acumen Pharmaceuticals, For: Aug 13August 13, 2024 7:48 AM Acumen Pharmaceuticals, Inc. (ABOS) Misses Q2 EPS by 7cAugust 13, 2024 7:22 AM Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 13, 2024 7:00 AM